Opioids for Treatment of Pre-hospital Acute Pain: A Systematic Review.

INTRODUCTION: Acute pain is a frequent symptom among patients in the pre-hospital setting, and opioids are the most widely used class of drugs for the relief of pain in these patients. However, the evidence base for opioid use in this setting appears to be weak. The aim of this systematic review was to explore the efficacy and safety of opioid analgesics in the pre-hospital setting and to assess potential alternative therapies.
METHODS: The PubMed, EMBASE, Cochrane Library, Centre for Reviews and Dissemination, Scopus, and Epistemonikos databases were searched for studies investigating adult patients with acute pain prior to their arrival at hospital. Outcomes on efficacy and safety were assessed. Risk of bias for each included study was assessed according to the Cochrane approach, and confidence in the evidence was assessed using the GRADE method.
RESULTS: A total of 3453 papers were screened, of which the full text of 125 was assessed. Twelve studies were ultimately included in this systematic review. Meta-analysis was not undertaken due to substantial clinical heterogeneity among the included studies. Several studies had high risk of bias resulting in low or very low quality of evidence for most of the outcomes. No pre-hospital studies compared opioids with placebo, and no studies assessed the risk of opioid administration for subgroups of frail patients. The competency level of the attending healthcare provider did not seem to affect the efficacy or safety of opioids in two observational studies of very low quality. Intranasal opioids had a similar effect and safety profile as intravenous opioids. Moderate quality evidence supported a similar efficacy and safety of synthetic opioid compared to morphine.
CONCLUSIONS: Available evidence for pre-hospital opioid administration to relieve acute pain is scarce and the overall quality of evidence is low. Intravenous administration of synthetic, fast-acting opioids may be as effective and safe as intravenous administration of morphine. More controlled studies are needed on alternative routes for opioid administration and pre-hospital pain management for potentially more frail patient subgroups.

Key Summary Points

Introduction

Acute pain remains a common symptom in patients requiring emergency care [1-4]. Early and appropriate relief of acute pain is recommended in the pre-hospital acute phase of care to ease transportation of the patient to the hospital while assuring patient comfort and reducing detrimental effects of pain and accompanying stress [5, 6]. For patients experiencing moderate to severe pain, opioids are widely accepted as the mainstay of analgesic therapy. A common pharmacodynamic feature of this drug class is an effective modulation of nociceptive transmission in the central nervous system [7, 8]. The more lipophilic character of newer synthetic opioid formulas compared with morphine may enable more rapid crossing of the blood–brain barrier, allowing them to reach the target organ within a few minutes [9]. This quick analgesic onset has made synthetic opioids the analgesic of choice in some pre-hospital services. However, the rapid analgesic offset of synthetic opioids demands continuous need for patient assessment and possibly repeated titration to maintain the analgesic effect, which is turn requires an emergency care clinician skilled in pain evaluation and analgesic dosing. All opioids carry a risk of life-threatening side effects which must be recognized and handled promptly [7, 10]. Also, opioids have a high abuse potential, which has caused an epidemic of opioid overdose in the USA and Europe. These factors have driven an intensified search for alternative analgesics [11, 12]. Even though the treatment of acute pain is a priority in pre-hospital care [13-19], the evidence base guiding treatment choices appears to be weak. Therefore, the aims of this systematic literature review on effective and safe opioid analgesia are: (1) to identify potential alternatives for intravenous opioids in pre-hospital emergency care; (2) to compare synthetic opioids with morphine in terms of relieving pain; (3) to assess whether effective and safe administration of opioids is related to the competency level (cadre) of the pre-hospital healthcare provider; (4) to examine whether alternative routes of opioid administration may be as effective and safe as intravenous administration; (5) to identify groups of patients in whom pre-hospital opioid administration should be waived or carried out with extra caution.

Methods

This systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions [20]. It is part of a comprehensive literature review (PROSPERO registration number: CRD42018114399) of studies on pre-hospital analgesia, with the aim to provide the basis for a clinical guideline on the subject. The review has similar methodologies as described elsewhere [21, 22]. The task force conducting the guideline was appointed by the Scandinavian Society of Anaesthesia and Intensive care medicine (SSAI) [23].

Inclusion Criteria

The following inclusion criteria were used:

Pre-hospital adult patients with acute pain

Synthetic opioids, other analgesics, no analgesics or opioids given by a different route of administration

Morphine administered intravenously

Pain reduction (change in pain scores); speed of onset; duration of effect; relevant adverse effects, such as nausea and vomiting; pruritus; hypotension; hypoxemia; and respiratory failure. Where investigated, serious outcomes, such as mortality and anaphylaxis, are reported

In addition to the endpoints listed in PROSPERO, our aim to assess whether effective and safe administration of opioids is related to the competency level of the pre-hospital healthcare provider. We therefore compared physicians with non-physicians. We included systematic reviews and randomized controlled trials (RCTs) of adult patients with acute pain, regardless of etiology, managed in the pre-hospital setting. Due to a limited number of studies, we also considered non-RCTs, cohorts with control group, interrupted time-series, and controlled before-after studies.

Exclusion Criteria

Studies including children and patients with chronic pain were excluded. Also excluded were studies not conducted in the pre-hospital setting (due to major concerns of indirectness), as well as conference abstracts and publications without results available in full text. Studies addressing the efficacy and safety of ketamine compared with opioids were explored in a previously published review conducted by the same task force [22]. Studies on inhaled analgesia (for example, methoxyflurane) will be reported in another review by the same task force.

Search Strategy

A medical research librarian developed the search strategy in collaboration with the authors. The following databases were searched from their inception: PubMed, EMBASE, Cochrane Library, Centre for Reviews and Dissemination, Scopus, and Epistemonikos. The most recent update of the search was conducted 4 January 2021. The complete search strategies are presented in Electronic Supplementary Material Appendix 1. Because few available studies were expected, we designed a broad search strategy so as not to miss any relevant studies—hence the relatively large number of references identified by the searches. The search was limited to articles published in English, Danish, Norwegian, and Swedish.

Study Selection

No assessor reviewed a study that they had (co-)authored. Three authors (LR and either KDF or PKH) independently assessed all titles and abstracts identified from the search according to the inclusion criteria, as described in our previous reviews [21, 22]. References considered to be potentially relevant were collected and assessed independently in full text by two assessors using the same inclusion criteria [21, 22]. Disagreements were resolved by discussion among all three assessors. Study selection was based on title and abstract. The full text and risk of bias was assessed using the Covidence online systematic review collaboration platform (Veritas Health Innovation, Melbourne, Australia) [24].

Assessment of Risk of Bias

In accordance with the Cochrane Handbook for Systematic Reviews of Interventions [20], the following items were assessed: (1) sequence generation; (2) concealment of allocation; (3) blinding of participants and personnel; (4) blinding of outcome assessor; (5) incomplete outcome data; (6) selective outcome reporting; and (7) other risk of bias. For non-RCTs and other studies with a control group, the following items were also assessed: (8) similarity of baseline characteristics; (9) similarity of baseline outcome data; and (10) free of contamination. All items were rated as high, unclear, or low risk of bias.

Data Extraction and Analysis

As described elsewhere [21, 22], we extracted data pertaining to full reference; study design and country in which the study was conducted; characteristics of the population (e.g., number of patients, age, gender, cause of pain, setting, and context); type and dose of analgesics given; competency of the healthcare personnel who administered the analgesic; comparison/control intervention; attrition; outcomes; and follow-up times.

Dichotomous outcomes are presented as the risk ratio (RR) with associated 95% confidence interval (CI). Continuous outcomes are presented as the mean difference between the groups (MD) with associated 95% CI. Where different scales were used to measure the same outcome, we calculated the standardized mean difference (SMD) with 95% CI. We used Review Manager version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) to generate forest plots. Due to substantial clinical heterogeneity between the included studies, meta-analyses were not undertaken. Several of the included studies reported results for each group without making a comparison between them; in these cases, we made these calculations using Review Manager version 5.3 to find the SMD (95% CI).

Grading our Confidence in the Evidence

Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, we graded our confidence in the evidence for each outcome and presented results as high, moderate, low, or very low quality [25]. The evidence across each outcome was assessed by eight criteria: five criteria could lower our confidence in the evidence, and three criteria could be used to consider upgrading evidence from observational studies that had not been downgraded [25]. According to GRADE, when the effect of interventions is assessed, RCTs start at high, and observational studies start at low [25].

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Results

The literature search identified 3453 papers, of which 125 were assessed in full text. Ultimately, 12 studies were included in this systematic review. A PRISMA flow diagram of study selection is given in Fig. 1. Table 1 provides a summary of the studies included in this review.

Fig. 1

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of study selection

Table 1

Summary of included studies

Reference/Study design/Country	Intervention	Comparison	Outcomes
Opioids versus placebo or no analgesic treatment
Puymirat et al. [29]/Retrospective cohort study/France	n = 453, morphine administration form or dose not described	n = 1985, no morphine administered in the prehospital setting	In-hospital death, 1-year survival
Morphine versus synthetic opioids
Galinski et al. [32]/RCT/France	n = 28, i.v. fentanyl dose of 1 μg/kg followed by additional doses of 30 μg until pain relief	n = 26, i.v. morphine dose of 0.1 mg/kg followed by additional doses of 3 mg until pain relief	Effect: Change in VAS (0–10) from baseline to 30 min after drug administration Safety: Comparison af various vital signs and side effects (nausea, dizziness, dysphoria, emesis, pruritus)
Bounes et al. [28]/RCT/France	n = 54, i.v. sufentanil dose of 0.15 μg /kg followed by additional doses of 0.075 μg/kg every 3 min until pain relief	n = 54, i.v. morphine dose of 0.15 mg/kg followed by additional doses of 0.075 mg/kg every 3 min until pain relief	Effect: Change in NRS (0–10) from baseline to 30 min after drug administration Safety: Comparison af various vital signs and side effects (nausea, emesis, dizziness and pruritus)
Smith et al. [26]/qRCT/USA	n = 100, i.v. fentanyl dose of 50 μg followed by additional four doses (maximum 250 μg) until pain relief	n = 104, i.v. morphine dose of 4 mg followed by additional four doses (maximum 20 mg) until pain relief	Effect: Change in NRS (0–10) from baseline to registration of final pain score Safety: Incidence of hypoxia (SpO2 < 95%), hypotension (SBP < 100 mmHg), pruritus and nausea or vomiting
Weldon et al. [30]/RCT/Canada	n = 88, i.v. fentanyl. A: Patients aged < 75 years and body weight > 50 kg, 50 μg every 5 min as needed to a maximum of four injections. B: Patients aged ≥ 75 years and/or body weight ≤ 50 kg, 25 μg every 5 min needed to a maximum of four injections	n = 99, i.v. morphine. A: Patients aged < 75 years and body weight > 50 kg, 5 mg every 5 min as needed to a maximum of four injections. B: Patients aged ≥ 75 years and/or body weight ≤ 50 kg, 2.5 mg every 5 min needed to a maximum of four injections	Effect: Change in VAS (0–10) and NRS (0–10) from baseline to 30 min after drug administration Safety: Comparison af various vital signs and side effects (nausea, emesis and apnoea). Incidence of hypotension (SBP < 90 mmHg)
Vergnion et al. [27]/RCT/Belgium	n = 53, i.v. tramadol. Initial dose 100 mg, followed by a further dose of 50 mg every 5 min to a maximum of 200 mg	n = 48, i.v. morphine. A: Patients with body weight < 71 kg: Initial dose 5 mg, followed by a further dose of 5 mg every 5 min to a maximum of 15 mg. B: Patients with body weight > 70 kg: Initial dose 10 mg, followed by a further dose of 5 mg every 5 min to a maximum of 20 mg	Effect: Change in VRS (0–3) from baseline to 40 min after drug administration Safety: Difference in sedation score and comparison of side effects (nausea and vomiting)
Silfvast et al. [31]/RCT/Finland	n = 16, i.v. alfentanil. Initial dose 0.5 mg, followed by a further dose of 0.5 mg to a maximum of 1 mg	n = 20, i.v. morphine. Initial dose 5 mg, followed by a further dose of 5 mg to a maximum of 10 mg	Effect: Difference in VAS (0–50) from baseline to 15 min after drug administration Safety: Comparison af various vital signs and side effects (nausea, dizziness and fatigue)
Fleischman et al. [35]/Observational before-after study/USA	n = 363, i.v. fentanyl. Initial dose 50 μg, followed by further doses of 25–50 μg every 3–5 min to a maximum of 200 μg	n = 355, i.v. morphine. Initial dose 2–5 mg, followed by further doses of 2–5 mg every 5 min to a maximum of 20 mg	Effect: Change in NRS (0–10) from baseline to registration of final pain score Safety: Comparison af various vital signs and side effects (nausea and vomiting). Incidence of hypoxia (SpO2 < 92% and 5% below baseline)
High competency level versus lower competency level
Lennssen et al. [36]/Retrospective cohort study/Germany	n = 149, paramedics supported by EMS physicians to administer morphine using a standard operating procedure	n = 199, pain treatment left to the discretion of the treating on-scene physician	Effect: Change in NRS (0–10) from baseline to end of mission Safety: Comparison af various vital signs and side effects (nausea and vomiting) or signs of respiratory- or circulatory insufficiency
Brokmann et al. [37]/Retrospective cohort study/Germany	n = 80, paramedics supported by EMS physicians to administer morphine using a standard operating procedure	n = 80, pain treatment left to the discretion of the treating on-scene physician	Effect: Change in NRS (0–10) from baseline to end of mission Safety: Comparison af various vital signs and side effects (nausea and vomiting)
Intravenous opioids versus intranasal opioids
Rickard et al. [33]/RCT/Australia	n = 127, i.n. fentanyl. Initial dose 180 μg, followed by two further doses of 60 μg given at 5-min intervals until pain relief	n = 100, i.v. morphine. Initial dose 180 μg, followed by two further doses of 60 μg given at 5-min intervals until pain relief	Effect: Change in NRS (0–10) from baseline to destination Safety: Comparison af various vital signs and side effects (low respiratory rate, hypotension, dizziness, nausea, bad taste, itching, watery eyes, nasal congestion, irritated throat, chest tightness, dysphoria/depression)
Middleton et al. [34]/Observational cohort study/Australia	n = 3778, i.n. fentanyl. Initial dose of 240 μg with subsequent doses of 60–120 μg every 5 min as required, no maximum dose	n = 12,955, i.v. morphine. Initial dose of 5 mg, followed by 2.5–5.0 mg every 2 min until pain relief to a maximum of 0.5 mg/kg	Effect: Change in NRS (0–10) from baseline to final pain score recording

CI Confidence interval, EMS Emergency Medical Service, i.v. intravenous, i.n. intranasal, n number, vs versus, NRS numeric rating scale, qRCT quasi-experimental RCT, RCT randomized controlled trial, SBP systolic blood pressure, SpO oxygen saturation, VAS visual analogue scale, VRS verbal rating scale

Characterization of the Trials

The 12 included studies were conducted in France (3), Australia (2), the USA (2), Germany (2), Canada (1), Belgium (1), and Finland (1) and included trauma patients [26-28], patients with chest pain [29-31], and patients with acute pain arising from various etiologies [32-37]. A total of 21,317 pre-hospital patients with acute pain were included: 917 patients in seven RCTs, 2601 patients in a controlled cohort study, 718 patients in a controlled before-after study, and 17,081 patients in three observational studies. Although one study included both adults and adolescents, the vast majority of patients were adults, as indicated by the median (95% CI) age, which was 59 (56–61) years in one group and 61 (59–63) years in the other group [35].

Various pain scales and outcomes were used in the 11 studies measuring efficacy, with seven studies reporting pain intensity on a verbal Numeric Rating Scale (NRS, 0–10) [27, 28, 33–37], three studies using the Visual Analogue Scale (VAS 0–100 [30, 32] or VAS 0–50 [31]), and one study reporting pain on a 4-point Verbal Rating Scale (VRS-4) [27]. Pain outcomes were reported as change in pain scores in ten studies [26, 27, 30–37] and pain relief (NRS < 4) 15 min after study drug administration in one study [28]. Seven studies used an unspecified observation period from baseline to hospital arrival [26, 27, 33–37], whereas four studies used fixed time-points of 15 min [28, 30, 31] or 30 min [32].

The studies were heterogenic in terms of safety reporting, with a widespread recording of various adverse effects: nausea [28, 30–32, 35–37], emesis [27, 28, 30, 32, 33], nausea and vomiting [27], fatigue [31], sedation (reduction in Glasgow Coma Scale or sedation score) [27, 28, 32, 35], dizziness [27, 28, 31–33], dysphoria [32, 33], confusion [28], headache [28], urticaria [28], and pruritus [27, 28, 32, 33]. Hypotension was defined differently by systolic blood pressure levels in three studies [27, 30, 33], and hypoxia or respiratory depression was defined by different cutoff values of peripheral oxygen saturation (SpO2) in five studies [26, 28, 30, 33, 35]. Most studies combined the rare events of adverse effects to one pooled estimate.

Risk of Bias Assessment

Some trials had high risk of bias, with the main reasons being lack of random sequence generation, lack of allocation concealment, and lack of blinding of patients, personnel, and/or outcome assessor (Fig. 2).

Fig. 2

Risk of bias table. Obs Observational study, qRCT quasi-RCT, RCT randomized controlled trial

Comparisons

The included studies covered four comparisons involving opioids (Table 2):

Table 2

GRADE summary of findings tables for the comparisons in the systematic review

Opioids [29] versus no analgesia or alternative drugs

Morphine (intravenous [i.v.]) versus synthetic opioids (i.v. fentanyl [26, 30, 32, 35], alfentanil [31], sufentanil [28], tramadol [27])

Physicians versus non-physicians [36, 37]

Opioids (i.v.) versus opioids given by another route of administration (intranasal fentanyl [33, 34]).

Analysis and Grading

Meta-analysis was not considered appropriate due to clinical heterogeneity; the studies differed substantially in terms of patient populations, interventions, comparisons, and outcomes.

Our confidence in the evidence was downgraded for various reasons (high risk of bias, inconsistency, indirectness, imprecision, and publication bias) as explained in the footnotes in Table 2. Below is a resume of the included studies for each of the comparisons.

Opioids Versus No Analgesia or Alternative Drugs

No pre-hospital studies comparing opioids with placebo, paracetamol, or non-steroidal-inflammatory drugs (NSAIDs) were identified. One pre-hospital register-based study involving 2438 patients with myocardial infarction assessed the risk related to receiving morphine for acute chest pain [29]. The study reported few events and uncertain in-hospital mortality (adjusted odds ratio [OR] 0.48, 95% CI 0.12–1.85), stroke (adjusted OR 0.49, 95% CI 0.06–4.46), stent thrombosis, bleeding or blood transfusion requirements compared with those who did not receive pre-hospital morphine (Table 2). In contrast to our review questions which considered morphine to be standard care, this study analyzed morphine as the intervention [29]. The comparison is equally relevant and was included.

Morphine (i.v.) Versus Synthetic Opioids (i.v.)

Synthetic opioids were compared with i.v. morphine in seven studies (Table 2; Figs. 3, 4). We did not combine these studies in meta-analysis due to clinical heterogeneity. Change in pain score for morphine versus intranasal fentanyl showed statistical heterogeneity (I2 = 71%), but morphine versus i.v. fentanyl did not (I2 = 0%). Adverse events showed statistical heterogeneity (I2 = 61%). Overall, moderate quality of evidence found similar results from using synthetic opioid and morphine in terms of analgesic effect. Low quality of evidence supports that synthetic opioids and morphine are similar in the proportion of reported adverse events.

Fig. 3

Forest plot illustrating change in pain scores for patients treated with synthetic opioids vs. morphine. CI Confidence interval, i.v. intravenous, SD standard deviation

Fig. 4

Forest plot illustrating adverse events in patients treated with synthetic opioids vs. morphine. RCT randomized controlled trial, qRCT quasi-RCT, Obs observational study, AE standard adverse events, i.v. intravenous, CI confidence interval, vs versus

In a small RCT (n = 54) on both trauma and non-trauma patients, Galinski et al. compared i.v. morphine with i.v. fentanyl and found no difference in the change in pain scores (SMD 0.11, 95% CI − 0.42 to 0.65, VAS 0–100) or vital signs, but did observe uncertainty regarding adverse effects (RR 1.08, 95% CI 0.54–2.16), nausea, emesis, dysphoria, pruritus, dizziness, and sedation) [32].

In a physician-staffed helicopter emergency medical service (n = 200), no difference was found in analgesic effect (change in mean pain scores: SMD − 0.09, 95% CI − 0.37 to 0.18, NRS 0–10), occurrence of hypoxia (SpO2 < 95%), hypotension (systolic blood pressure < 100 mmHg) or adverse effects (no events of pruritus or nausea or vomiting) when comparing i.v. morphine to i.v. fentanyl [26].

Weldon et al. found no difference in analgesic effect (difference in pain scores [NRS] every 5 min until 30 min, P = 0.47) of i.v. fentanyl compared with i.v. morphine in patients with chest pain (n = 207). The researchers also found similar vital signs and similar adverse effects (RR 1.59, 95% CI 0.98–2.58), including nausea (12.5% [n = 11] vs. 18.2% [n = 18], P = 0.32), apnea (none), emesis (1.1% [n = 1)] vs. 2.0% [n = 2], P = 1.0), and antihistamine given (8.0% [n = 7] vs. 9.1% [n = 9], P = 0.8) [30].

A small Finnish study with 36 patients found faster and more effective immediate pain reduction when using i.v. alfentanil compared with i.v. morphine. However, at the end of the observation period only two of 20 patients (10%) in the morphine group expressed recurring pain compared with four of 16 (25%) in the alfentanil group. A non-significant trend of more adverse effects (dizziness, fatigue, and nausea: n = 5 ([1%] vs. n = 1 [5%]) in the alfentanil group was observed. The study also found similar vital signs in both groups [31].

A French study (n = 108) on sufentanil, another fast-acting opioid, reported a similar analgesic effect of i.v sufentanil compared with i.v morphine (difference in proportion of patients with NRS < 4 at 15 min: 4% [95% CI − 13 to 21]). Results regarding vital signs and adverse effects (multiple; see Table 1) were non-conclusive (RR 1.00, 95% CI 0.45–2.21) [28].

Fleischman et al. implemented paramedic-administered i.v. fentanyl and investigated the effect of this action in a diverse group of patients (n = 363). The authors found that pain (NRS) was reduced by 3.1 units (95% CI 2.8–3.4) in the fentanyl group compared with 2.9 units (95% CI 2.5–3.2) in the group receiving i.v. morphine (n = 355) before protocol change (difference between the groups: SMD − 0.06, 95% CI − 0.21 to 0.09). The authors found similar reported numbers of adverse events (RR 1.49, 95% CI 0.91–2.45), nausea, hypotension (SBP < 90 mmHg), respiratory depression (RR < 12/min), hypoxemia (SpO2 < 92%), and sedation (any decrease in GCS from baseline)) [35] in the two groups.

Finally, Vergnion et al. compared i.v. morphine with i.v. tramadol in 101 trauma patients. The groups were similar in terms of change in pain scores (VRS, 0–100: − 1.19 ± 0.71 [morphine] vs. − 1.21 ± 0.70 [tramadol]; difference: SMD − 0.03, 95% CI − 0.42 to 0.36), vital signs, and adverse events (nausea and vomiting) [27].

Physicians Versus Non-physicians

Two observational studies explored the possible effect of competency level of the attending clinician on the efficacy and safety of opioid administration (Table 2; Fig. 5). The overall quality of evidence was very low. Clinical heterogeneity prevented meta-analysis (statistical heterogeneity: I2 = 63).

Fig. 5

Forest plot illustrating change in pain scores for patients treated by physicians versus paramedics. SD standard deviation, i.v. intravenous, CI confidence interval, vs versus

Lennssen et al. assessed the efficacy and safety of opioid therapy provided by paramedics compared with opioid therapy provided by pre-hospital physicians and found no difference in effect (change in NRS: 4.94 ± 2.01 and 4.84 ± 2.28, respectively; P = 0.5379) or in the proportion of reported adverse events between the groups [36].

In a similar setup in Germany, Brokmann et al. found that analgesia was less effective in patients treated by telemedically-supported paramedics compared with patients treated by physicians (change in NRS: 3.78 ± 2.0 and 4.38 ± 2.2, respectively; P = 0.0159). No adverse events were reported in either group [37].

Opioids (i.v.) Versus Opioids Given by Another Route of Administration

Two pre-hospital studies have explored the safety and/or efficacy of non-intravenous administration of opioids compared with i.v. opioid administration (Table 2; Figs. 3, 4). The overall quality of evidence was low for effect and very low for adverse events.

Rickard et al. randomized a miscellaneous patient group to receive either i.v. morphine (n = 100) or intranasal fentanyl (n = 127) and found similar analgesic effect (change in NRS: 3.57 [95% CI 3.10–4.03] vs. 4.22 [95% CI 3.71–4.71]) in the two groups but reported a higher incidence of adverse events (see Table 1) in the group receiving intranasal fentanyl. Additionally, rescue analgesia was needed significantly earlier in patients given intranasal fentanyl compared with patients receiving i.v. morphine [33].

Middleton et al. found no difference in the change in pain scores (NRS: 4.5 [95% CI 4.5–4.6] vs. 4.5 [95% CI 4.4–4.6]) when comparing i.v. morphine with intranasal fentanyl in a large pre-hospital observational study. Adverse events were not reported [34].

Opioids use in Frail Patients

No pre-hospital studies assessed the risk of opioid administration in different groups of frail patients, such as geriatric patients, pregnant patients or patients with comorbidities.

Discussion

In this systematic review investigating the pre-hospital administration of opioids for acute pain, both the number of relevant studies and the overall quality of evidence were low. The use of different pain scales (some not validated) by different author groups confuses evidence interpretation, hampers the possibility of meta-analysis, and confounds clear guidelines on pre-hospital pain management. Most previous reviews on the topic have been narrative [5, 14, 3839], solely focused on trauma patients [19], or have increased the risk of indirectness by including the evidence based on emergency department (ED) studies [40, 41].

Opioids Versus No Analgesia or Alternative Drugs

We found no studies comparing the use of no analgesia or alternative, non-ketamine analgesic drugs with i.v. opioids in pre-hospital emergency care.

The published pre-hospital literature on opioids is characterized by being of low to very low quality based on single-arm feasibility studies reporting a reduction in pain during pre-hospital transport, a small number of side effects, and low occurrence of abnormal vital signs. From a clinical point of view, i.v. opioids are often needed to relieve severe acute pain, and they appear to be generally effective and safe when titrated cautiously to a monitored patient.

RCTs comparing opioids with placebo or weaker analgesics with a more beneficial safety profile cannot be conducted in an ethically safe way in the subset of patients with severe acute pain. For patients with mild or moderate pain, alternatives to opioids might be available and should be explored in future RCTs.

Recent pre-hospital studies have found an increased effect when combining ketamine with opioids, but also a higher incidence of adverse effects [42-44], compared with opioid-only therapy. The added analgesic effect of a combined therapy has been confirmed in an ED context [45], while a benefit of ketamine compared with morphine as monotherapy has not been demonstrated [46-48]. Inconclusive results appear when pooling the scarce evidence in a recent systematic review [22]. Other systemic analgesic adjuvants (e.g., midazolam and metoprolol) to i.v. morphine have been tested in the pre-hospital setting, but not proven to be effective [49, 50].

Morphine (i.v.) Versus Synthetic Opioids (i.v.)

We found moderate evidence that i.v. morphine and synthetic opioids are equally effective. There are uncertainties due to the few reported serious adverse events (low quality) or other adverse events (very low quality) both from i.v. morphine and synthetic opioids. Rapid analgesic onset may be a desirable feature of the newer synthetic opioids when applied in a pre-hospital setting. However, if not titrated sufficiently, the analgesic effect vanishes quickly, and for this reason morphine could be just as suitable in terms of relieving pain in the entire course of the pre-hospital patient care [51] as the synthetic alternatives.

Physicians Versus Non-physicians

Few studies have explored the possible impact of competency level of the pre-hospital healthcare provider on the efficacy and safety of opioid administration. The overall quality of evidence was very low, thus not allowing us to draw any conclusion. Intuitively, the quality of the pain management may be linked to the educational level of the clinicians.

We acknowledge that our distinction between physicians and non-physicians is a very crude way of addressing competency level as this may very well be more dependent on other factors, such as training and exposure, than on formal education [52, 53]. Therefore, we suggest that future focus should be on prioritizing repeated multifaceted educational efforts and continuous adjustments of pain management protocols in order to improve the quality of acute pain management [54-57].

I.v. Opioids Versus Opioids Given by Another Route of Administration

Low-quality evidence indicates a similar effect between i.v. morphine and intranasal fentanyl, but with a higher incidence of rescue analgesia and adverse events among patients receiving intranasal fentanyl. It may be worth noting that these studies compare groups of patients where both the agent and the route of administration differ between the groups. From a clinical point of view, analgesics with an easy administration profile may play a role in pre-hospital pain management, especially in cases where i.v. access is difficult or infeasible, such as in children or heavily obese patients.

Opioids for Frail Patients

We found no studies identifying groups of patients in whom pre-hospital opioid administration should be waived or carried out with extra caution. Theoretically, the risk of opioid accumulation increases with repeated administrations and larger cumulative doses affecting the duration of the analgesic effect as well as the occurrence of side-effects [58]. The magnitude and duration of analgesic effect is also highly individual and affected by numerous factors, such as age, comorbidity, obesity, frailty, and concomitant use of central nervous system depressants [7]. Potential side effects are numerous and should be recognized and handled promptly because some are potentially life-threatening [7, 10, 59]. Therefore, a cautious approach to frail patients seems sensible.

Studies from Other Settings

In a recent systematic review and meta-analysis by Sobieraj et al., the evidence for pre-hospital acute pain management was mainly based on ED studies [41]. These authors searched for alternatives to opioids and included 52 RCTs and 13 observational studies comparing the efficacy of opioids to that of ketamine, acetaminophen, nitrous oxide, and NSAIDs. They concluded that ketamine and opioids provided similar analgesia and that opioids seemed to have fewer side effects. The combined administration of ketamine and opioids seemed to relieve acute pain more than opioids as monotherapy [41].

Comparing opioids to acetaminophen or NSAIDs in these ED studies, Sobieraj et al. demonstrated no difference in reduction in pain scores [41]. Compared with patients given acetaminophen, more patients given opioids experienced dizziness whereas there was no difference in hypotension, sedation, or respiratory depression. It should be noted that patients included in ED pain studies may differ from those in pre-hospital studies in terms of initial pain status and clinical conditions and that the authors’ exclusion of patients with severe pain may limit generalizability of findings to a broad spectrum of patients. Therefore, careful attention should be paid when extrapolating results from ED studies to the pre-hospital setting.

Conclusion

The evidence base for pre-hospital opioid administration to relieve acute pain is scarce and the overall quality of evidence low. The i.v. administration of synthetic, fast-acting opioids seems to be as effective and as safe as the i.v. administration of morphine. More controlled studies are needed to investigate alternative routes for opioid administration as well as pre-hospital pain management of potentially more frail patients.

Below is the link to the Electronic Supplementary Material.

Supplementary file1 (PDF 235 KB)

Opioids are frequently used as treatment for acute pain in pre-hospital patients.

Twelve studies were included in a systematic review to assess the efficacy and safety of opioids in this setting.

Several studies had high risk of bias, resulting in low or very low quality of evidence.

Studies on pre-hospital opioid administration to relieve acute pain is scarce and overall quality of evidence is low.